Poolbeg Pharma’s (POLB) House Stock Rating Reaffirmed at Shore Capital Group

Poolbeg Pharma (LON:POLB)‘s stock had its “house stock” rating restated by research analysts at Shore Capital Group in a research note issued to investors on Tuesday,London Stock Exchange reports.

Poolbeg Pharma Stock Up 3.9%

Shares of POLB stock opened at GBX 7.90 on Tuesday. Poolbeg Pharma has a twelve month low of GBX 2.50 and a twelve month high of GBX 9. The business’s fifty day moving average is GBX 5.34 and its 200 day moving average is GBX 4.64. The stock has a market cap of £55.70 million, a price-to-earnings ratio of -8.40 and a beta of 1.82.

Poolbeg Pharma (LON:POLB) last announced its quarterly earnings data on Tuesday, April 28th. The company reported GBX (0.94) earnings per share (EPS) for the quarter. Equities research analysts expect that Poolbeg Pharma will post -0.68 earnings per share for the current fiscal year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.